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A four-compartment PBPK heart 
model accounting for cardiac 
metabolism - model development 
and application
Zofia Tylutki1 & Sebastian Polak1,2
In the field of cardiac drug efficacy and safety assessment, information on drug concentration in heart 
tissue is desirable. Because measuring drug concentrations in human cardiac tissue is challenging 
in healthy volunteers, mathematical models are used to cope with such limitations. With a goal 
of predicting drug concentration in cardiac tissue, we have developed a whole-body PBPK model 









concentration in various locations within heart tissue using a PBPK approach.
According to current cardiac safety assessment guidelines, the focus is placed on in vitro hERG channel blockade1 
as a predictive factor of in vivo QT interval prolongation1, which serves as a surrogate for torsades de pointes 
arrhythmia (TdP). However, the paradigm is shifting to other approaches. Among new recommended strategies 
are in silico mechanistic models of the human ventricular action potential and the assessment of drug effects on 
multiple cardiac currents in in vitro human models2,3.
The effect (extent of the delayed ventricular repolarization) should be related to the concentration of the test 
substance. The plasma concentration is most commonly used as the effective concentration surrogate due to the 
relatively high availability, yet it can be an imperfect substitute, especially for some types of chemical moieties 
(i.e., highly lipophilic). Drug concentration in heart tissue should be of particular interest regarding all possible 
sites where the drug might meet cardiac ion channels. It should gain even more prominence in light of reports 
that note that myocardial drug concentration better correlates with a change in QT length4,5 and that the tis-
sue drug concentration profiles do not necessarily correlate with those in plasma6. Although measurements of 
drug concentration in human cardiac tissue seem impossible in patients not undergoing open heart surgery, the 
mathematical models do not face such limitations. A physiologically based pharmacokinetic (PBPK) modeling 
approach is considered a useful tool in tracking the concentration-time profiles of drugs in different tissues, based 
on in vitro data. Moreover, the mechanistic nature of PBPK allows for the creation of universal, drug-independent 
models7,8. The power of the idea lies in the fact that parameters describing PBPK models have their physiological 
meaning and that the compartments represent body’s organs and tissues. In recent years, there has been a signif-
icant rise in the interest of PBPK modeling by the pharmaceutical industry, impacting regulatory decision mak-
ing. The models not only predict the pharmacokinetics but also can predict local drug concentrations to assess 
drug efficacy and safety7,9,10. A whole-body PBPK model usually treats tissues as homogeneous, ‘well-stirred’ 
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compartments, not accounting for regional differences in drug concentrations within the tissue. Thus, Gaohua et al.11 
proposed a multicompartment permeability-limited lung PBPK model applied to predict tuberculosis drug levels 
in the epithelial lining fluid and the lung tissue mass. Westerhout et al.12 developed a system-based pharmacoki-
netic model to describe the intra-brain drug distribution in rats. Neuhoff et al.13 built a PBPK kidney model under 
the name ‘MechKim’ to predict renal elimination. The model was also capable of simulating drug-drug interac-
tions at the level of transporter inhibition14. According to our knowledge, there is a lack of such a detailed PBPK 
model for heart tissue. We aimed to fill the gap by providing a four-compartmental heart PBPK model structure 
as a basis for predicting drug distribution within cardiac tissue.
Materials and Methods
System-related input parameters. Whole-body PBPK model input parameters. The basic whole-body 
PBPK after Jones and Rowland-Yeo8 was implemented and used as a scaffold in which to nest the developed mul-
ticompartment heart model. The model assumed perfusion rate-limited kinetics, which means that the blood flow 
to the tissues (compartments) was the limiting process. The values of body weight-dependent fractional tissue 
volumes, fractional tissue blood flows, cardiac output and microsomal protein per gram of human liver (MPPGL) 
were from the provided code [Table 1]. The model assumed a reference human of 70 kg.
The perfusion rate-limited model works under the assumption that total drug concentrations in the tissue and 
in the plasma at steady state are in the equilibrium with each other. Tissue-to-plasma water partition coefficients 
(Kps), which define that concentration balance, were predicted in Simcyp Simulator v.14.1 using the Rodgers et al. 
method15,16. Kp defining the drug partition between plasma and the rest of the body (Kpre) was fitted. Non-linear 
hepatic metabolism according to Michaelis-Menten enzyme kinetics was incorporated into the model equations. 
The values of the maximal rate of saturating substrate concentrations (Vmax) in [mg/h] for each CYPs isoform 
considered in the model were calculated according to the Equations (1).




Fractional adipose volume 0.213 L/kg
Fractional bone volume 0.085629 L/kg
Fractional brain volume 0.02 L/kg
Fractional gut volume 0.0171 L/kg
Fractional heart volume 0.0047 L/kg
Fractional kidney volume 0.0044 L/kg
Fractional liver volume 0.021 L/kg
Fractional lung volume 0.0076 L/kg
Fractional muscle volume 0.4 L/kg
Fractional skin volume 0.0371 L/kg
Fractional spleen volume 0.0026 L/kg
Fractional venous volume 0.0514 L/kg
Fractional arterial volume 0.0257 L/kg
Fractional plasma volume 0.0424 L/kg
Fractional erythrocytes volume 0.0347 L/kg
Fractional rest of body volume 0.109771 L/kg
Cardiac output 108.33 mL/s
Fractional adipose blood flow 0.05 —
Fractional bone blood flow 0.05 —
Fractional brain blood flow 0.12 —
Fractional gut blood flow 0.146462 —
Fractional heart blood flow 0.04 —
Fractional kidney blood flow 0.19 —
Fractional hepatic blood flow (venous side) 0.215385 —
Fractional lung blood flow 1 —
Fractional muscle blood flow 0.17 —
Fractional skin blood flow 0.05 —
Fractional spleen blood flow 0.017231 —
Fractional rest of body blood flow 0.114615 —
Microsomal Protein Per Gram of Human 
Liver (MPPGL) 45 mg/g
Table 1.  Whole-body PBPK input parameters after Rowland and Yeo8.
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 Vmax_pmol-maximal rate of saturating substrate concentrations [pmol/min/pmol of CYP], CYP-CYP abundance 
in average human liver [pmol/mg of microsomal protein],
MPPGL - Microsomal protein per gram of human liver [mg/g]
Vli - total liver volume [L]. MW-molecular weight of the compound [g/mol],
Heart model input parameters. The physiological and anatomical data were derived from the literature to reflect 
the physiology of the normal human heart. They are presented in Table 2.
The parameter describing blood flow through the pericardium (Qpf) was unknown and fitted in the optimiza-
tion process. It was subtracted from the Qhe to keep the sum of blood flow rates equal to cardiac output specified 
in the model. The Kps values between plasma and the epicardium (Kpepi), midmyocardium (Kpmid), and endocar-
dium (Kpendo) were in the same ratio as those derived from Garcia et al.’s publication on saxitoxin poisoning17, i.e., 
1:2.5:5, respectively. We took into account drug elimination in cardiac tissue as cytochrome P450 enzymes were 
detected in human cardiovascular tissue18–20. The values of mean microsomal fractions of the human heart for 
CYP enzymes (CYP2C8, CYP2C9, and CYP2J2) were used in computing total cardiac clearance in Equations (2) 
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where:
CLint2C8_per_mg - intrinsic clearance per mg of protein [mcL/min/mg],
CLint2C8_per_pmol - intrinsic clearance per pmol of CYP2C8 isoform [mcL/min/pmol],
CYP2C8 - Mean CYP2C8 enzyme abundance in the human heart [pmol/mg],
CLint 2C8 - Intrinsic clearance for CYP2C8 in the human heart [L/h],
Whe - average heart weight [g],
CLuint 2C8 - intrinsic clearance for CYP2C8 based on unbound fraction of compound [L/h],
fumic - fraction of drug unbound in an in vitro microsomal preparation,
ISEF2C8 - Inter System Extrapolation Factor for CYP2C8.
Intrinsic clearances based on unbound fractions of amitriptyline for CYPs 2C9 (CLuint2C9) and 2J2 (CLuint2J2) 
were calculated analogically and added to calculate the total heart metabolic clearance according to Equation (3).


















CLuint - total unbound intrinsic clearance per heart [L/h],
CLmHT - total heart metabolic clearance [L/h],
Qhe - total heart blood flow [L/h],
fup - fraction of drug unbound in plasma,
BP - blood to plasma concentration ratio.
Drug-specific input parameters. The proposed PBPK model incorporating the permeability-limited (assuming 
the permeability across cell membranes being the limiting process) heart model was used to simulate plasma and 
cardiac concentrations of amitriptyline as an exemplary drug23. Physicochemical and PK parameters for amitrip-
tyline used in a simulation scenario are listed in Table 3.
Parameter Symbol Value Unit References
Fraction of total heart volume for epicardium Vepi/Vhe 0.1 — 47
Fraction of total heart volume for midmyocardium Vmid/Vhe 0.3 — 47
Fraction of total heart volume for endocardium Vendo/Vhe 0.6 — 47
Volume of pericardial fluid Vpf 0.03 L 47
Relationship between Kps for heart layers Kpepi:Kpmid:Kpendo 1:2.5:5 — 17
Mean CYP2C8 enzyme abundance in human heart CYP2C8 0.2 pmol/mg 19
Mean CYP2C9 enzyme abundance in human heart CYP2C9 5.5 pmol/mg 19
Mean CYP2J2 enzyme abundance in human heart CYP2J2 0.17 pmol/mg 19
Table 2.  Physiological and anatomical data on heart tissue used as heart PBPK model-specific input 
parameters.
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The oral bioavailability of amitriptyline is highly variable, ranging from 33 to 62%; thus, the fraction absorbed 
(Fabs) was fixed at 0.5 (50%)24,25. The value of the first order absorption rate (ka) could not be found in reports, so 
ka [h−1] was adjusted to the observed data. The percentage of unbound drug in the plasma (fup) differs between 
studies from 3% to 7.4%24–30, so the fup value was fixed at 0.05 (5% of the free fraction). Because of the lack of 
information regarding the amitriptyline free fraction in pericardial fluid (fupf), the fupf was assumed to equal 
fup. A blood to plasma ratio (BP) of 1.04 was derived from25. The utilized value is in the range of other measured 
values, i.e., 0.86–1.1324,31.
The fixed Kp values were 3.0 (Kpepi), 7.4 (Kpmid)32, and 14.0 (Kpendo). The Kp value between plasma and peri-
cardial fluid was fixed at 2.633.
The liver metabolism considered amitriptyline biotransformation by CYP isoforms 1A2, 2B6, 2C8, 2C9, 2C19, 
2D6, and 3A434,35. The values of the maximal rate of saturating substrate concentrations (Vmax), Michaelis con-
stants (Km) and Inter System Extapolation Factors (ISEF) used in the model are reported in the Table (4).  We 
used 0.014 as the value of unbound fraction in hepatocytes (fuh), which was reported to be the highest bound 
of the range of fuh studied for imipramine and propranolol by Hallifax and Houston36. The intrinsic clear-
ances denoting amitriptyline N-demethylation by CYPs 2C8 and 2C9 were 0.072 and 0.079 mcL/min/pmol37. 
Amitriptyline does not undergo CYP 2J2 metabolism38. fumic and ISEF factors were assumed to equal 1. The 
literature value of octanol/water partition coefficient (Log P) was 4.6239.
Clinical and simulation data. The mean plasma concentrations of amitriptyline after administration of a single 
oral dose of 25 mg (as amitriptyline is taken as a hydrochloride salt, pure amitriptyline counts for 22 mg to which 
the model was fitted) were observed by Curry et al.40 in ten healthy men. The corresponding maximal concentra-
tion in heart tissue was set to 114.35 ng/mL at 3.5 h postdose based on pig data41. Two additional concentration 
values in heart tissue referring to the absorption phase and two in the elimination phase were set to make the 
fitting process feasible.
Software used. The model was written in R v.3.3.0. Numerical solutions were computed using deSolve library 
v.1.1342. The system of ordinary differential equations was integrated using the LSODA method43. Model fitting 
was performed with algorithms from FME package v.1.3.244. The weighted residuals (resi,l) of the model output 













Parameter Symbol Value Unit Reference
Fraction of administered dose absorbed Fabs 0.5 — 24,25
Fraction of unbound drug in plasma fup 0.05 — 24–30
Fraction of unbound drug in pericardial fluid fupf 0.05 — Assumption
Blood to plasma concentration ratio BP 1.04 — 25
Midmyocardium to plasma partition coefficient Kpmid 7.4 — 32
Pericardial fluid to plasma partition coefficient Kppf 2.6 — 33
Fraction of unbound drug in hepatocytes fuh 0.014 — 36
Renal clearance CLrenal 0.504 L/h 37
Intrinsic clearance per pmol of CYP2C8 CLint2C8_per_mol 0.072 mcL/min/pmol 34
Intrinsic clearance per pmol of CYP2C9 CLint2C9_per_mol 0.079 mcL/min/pmol 34
Intrinsic clearance per pmol of CYP2J2 CLint2J2_per_mol 0.000 mcL/min/pmol 38
Fraction of unbound drug in an in vitro microsomal preparation fumic 1 — Assumption
Inter System Extrapolation Factor ISEF 1 — Assumption
Log of the octanol-water partition coefficient for the compound Log P 4.62 — 39
Table 3.  Amitriptyline input parameters used in the simulation.
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 CYP2C8 CYP2B6
Vmax [pmol/min/
pmolCYP] 1.79 3.97 4.22 1.49 3.37
† 0.7 0.25
Km [μ M] 63.5 50.5 8.52 7.12 213.8 9.74 56.7
ISEF 11.1 5.73 3.07 0.74 3.92 3.7 3.7
Table 4.  Values of parameters used to describe non-linear hepatic metabolism according to Michaelis-
Menten enzyme kinetics. Values are after34. †Denotes another source of data i.e.,35. ISEF values correspond to 
B-Cell Lymphoma model and are taken from Simcyp Simulator. 
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where Modi,l is the modeled value, Obsi,l is the observed value, and errori,l is a weighting factor. For errori,l the 
modCost default value, i.e. 1, was chosen.
Simcyp Simulator45,46 v 14.1 (a Certara company) was used to predict Kp values for tissues represented in the 
full PBPK model. The diagram (Fig. 1) depicts the modeling workflow.
Results
Model structure. The structure of the final whole-body PBPK model is shown in Fig. 2.
The following is written as a set of ordinary differential equations (Equation 5 in the Appendix).
The model consisted of seventeen perfusion-limited compartments representing the following tissues: arterial 
blood, lung, adipose, bone, brain, kidney, spleen, gut, liver, muscle, skin, the rest of the body, venous blood, and 
the heart. Four compartments representing heart tissue were embedded into the whole-body PBPK structure. The 
added compartments stood for epicardium, midmyocardium, endocardium, and pericardial fluid, defined by the 
following volumes [L]: 0.0329, 0.0987, 0.1974, and 0.03, respectively. Epicardial, midmyocardial, and endocardial 
cells were set to constitute 10%, 30%, and 60% of the total heart tissue mass, according to Drouin et al.47.
The blood flow to the epicardium, midmyocardium, and endocardium was assumed to be equal, i.e., 4% of 
the cardiac output8. Arterial blood was assumed to perfuse the heart wall from the outward layer (epicardium), 
through the midmyocardium, to the most inner layer (endocardium). The blood left the cardiac tissue from the 
endocardium and returned to the venous blood compartment.
The pericardial fluid was perfused directly by arterial blood. Blood leaving the pericardial fluid entered the 
venous blood compartment directly.
The model also accounted for a drug disposition between the cardiac mass and pericardial fluid; it was 
described by passive disposition through the epicardial layer occurring in both directions. The parameters 
describing the permeability-limited process were grouped into one parameter (P) to simplify the model.
Physiological parameters describing the model structure were assumed to be constant, the compartments 
were homogeneous, and the equilibrium between the blood and tissues was reached immediately. The values of 
fup and fupf were assumed to be equal.
The proposed model assumed that the elimination occurred from the liver, kidney, and heart (tissue mass 
compartments). The implemented elimination clearances from the epicardium, midmyocardium, and endocar-
dium contributed one-third each of the total cardiac metabolic clearance.
Modeling the PK of amitriptyline. The Kps predicted in Simcyp Simulator for the amitriptyline com-
pound are presented in Table 5.
The calculated amitriptyline clearances was 0.316 L/h for total cardiac clearance. The renal clearance was set 
as 0.504 L/h according to Turner et al.37.
The first simulation was run to fit Kpre and ka [h−1] parameters to the observed amitriptyline concentration in 
plasma by Curry et al.40. Qpf [L/h] and P [L/h] were fixed at 0.01 and 0.40 as start parameters. The estimates (SD - 
standard error, p-value) are: ka = 0.80075 (0.03171, p = 4.33×10−11), and Kpre = 52.60950 (7.64768, p = 2.66×10−5). 
Figure 1. The modeling workflow. The color codes are as follow: blue, computational tool; green, data sources; 
orange, final outputs.
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These values were used in the second simulation performed to estimate Qpf and P (the model was fitted to the set 
heart concentrations). The estimates (SD, p-value) are as follows: Qpf = 0.01193 (0.09783, p = 0.911), P = 0.78230 
(5.76931, p = 0.901) (Table 6).
Simulated time-concentration profiles and observed/set data are presented in Figs 3, 4 and 5.
The goodness of fit is depicted in Figs 6 and 7. There was good agreement between the observed data and 
model-predicted profiles. However, the highest observed value was not captured. The plots revealed no systemic bias.
Discussion
Regarding cardiovascular drug safety assessment and cardiac medication development, understanding active-site 
drug concentration is of great need. However, direct measurements pose problems, and prediction remains chal-
lenging. Because PBPK modeling makes predicting tissue concentration-time profiles possible, we focused on 
cardiac tissue and applied a PBPK quantitative mechanistic framework to develop a heart model structure.
Herein, the proposed heart model reflects a simplification of human cardiac anatomy and physiology. The 
assumption about equal blood perfusion throughout all three layers of the cardiac wall may be justified as it is 
claimed that “flow per gram of subendocardial myocardium is at least equal to flow per gram of subendocardial 
myocardium”48. The order of perfused compartments describes, in the simplest manner, the coronary tree that, 
arising from the right and left coronary arteries, forms a subepicardial system whose branches perforate more 
inner heart wall layers49. Pericardial fluid hypothetically forms in two ways, i.e., first by plasma ultrafiltration 
and secondly by the overflow of a small amount of interstitial fluid from the underlying myocardium50,51. Thus, 
blood flow and diffusion from a neighboring epicardial layer were applied in the model as possible routes for drug 
Figure 2. The structure of the final whole-body PBPK model. The model consisted of seventeen perfusion-
limited compartments. The heart tissue was represented by four compartments, i.e., epicardium (EPI), 
midmyocardium (MID), endocardium (ENDO), and pericardial fluid (PF).
Adipose Bone Brain Gut Kidney Liver Lung Muscle Skin Spleen
Kpad Kpbo Kpbr Kpgu Kpki Kpli Kplu Kpmu Kpsk Kpsp
4.27 4.28 2.78 11.97 6.52 20.16 2.09 10.04 5.73 11.24






Table 6.  Results of the fitting process.
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distribution within cardiac tissue. The estimate of Qpf at 0.01 L/h, which contributes 0.076% of total cardiac blood 
flow, seems realistic although there are no published measured results to support that value.
Amitriptyline was chosen as a subject of the simulation because tricyclic antidepressants are said to distribute 
within tissues extensively32,52 and to induce cardiotoxicity23. According to CredibleMeds classification53 supported 
Figure 3. Simulation results. The time-amount of the amitriptyline profile (solid blue curve) resulted from 
fitting the model to values measured (solid black dots) by Curry et al.40.
Figure 4. Simulation results. Time-concentration profiles of amitriptyline in venous plasma (solid blue curve), 
pericardial fluid (solid green curve), and heart tissue in total (solid red curve) resulted from fitting the model 
to values measured by Curry et al. in healthy volunteers’ plasma40 (solid black dots) and to data set according to 
the amitriptyline concentration observed in pig heart41 (open black circles).
Figure 5. Simulation results. Time-concentration profiles of amitriptyline in heart tissue in total (solid green 
curve), in epicardium (solid blue curve), midmyocardium (solid violet curve), and the endocardium (solid red 
curve) data set according to the amitriptyline concentration observed in pig heart41 is depicted as open black circles.
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by the published case reports of TdP54, amitriptyline poses a conditional risk of TdP arrhythmia. Thus, its concen-
tration in cardiac tissue is worth being studied.
Regarding predicted amitriptyline absorption, the highest plasma concentration was achieved 1.3 h postdose 
whereas mean Tmax in the Curry et al.40 publication was 2.5 h. These differences most likely result from the over-
simplified equation describing the absorption process. The estimated absorption rate constant being 0.80 [h−1] 
refers to the absorption of amitriptyline according to the first order kinetics. The more complex solution will be 
proposed in the next step of developing the model structure described herein.
The perfusion-limited distribution followed the Kps values predicted in Simcyp Simulator (Table 5). Kpre value 
defining the drug partition between plasma and the rest of the body was estimated as 52.6 suggesting a higher 
accumulation of amitriptyline in parts of the human body other than considered in our model, or the active trans-
port being engaged in the disposition process. The model-predicted amitriptyline concentrations in the heart 
sub-model compartments, ranked in ascending order, are as follows: epicardium, midmyocardium, endocardium, 
and pericardial fluid. The maximal heart concentration is achieved at 1.7 h postdose. At that time point, the ratios 
of the concentrations in the sites in question to the concentration in venous blood are 2.89 for epicardium, 7.13 
for midmyocardium, 13.41 for endocardium, 42.65 for pericardial fluid, and 10.47 for the total heart. All of these 
values (except for pericardial fluid, which is too high according to postmortem findings34 and pericardial fluid 
composition is similar to plasma55) are within the range of heart Kp values reported in the forensic and animal 
studies41,56,57, which supports the feasibility of the model and will be further tested to validate effective concen-
tration surrogates. The disposition within the cardiac wall follows the assumed pattern after a postmortem study 
by Garcia et al.17; however, in animal studies, there were no appreciable gradients observed and homogeneous 
transmural drug distribution was described58,59. Therefore, investigating the disposition between cardiac mural 
layers requires more mechanistic insight, most likely with a permeability-limited kinetics assumption. The same 
case is with predicting drug concentration in the pericardial fluid compartment. Without the support of more 
mechanistic data allowing to describe the permeability process across the membrane of the epicardium, the P 
Figure 6. Observed values versus predicted values in the whole-body PBPK model. Solid black triangles 
represent data on the venous plasma amitriptyline amount. Open black triangles represent data on the 
amitriptyline amount in heart tissue.
Figure 7. Plot of the residuals. Solid black dots refer to results from the 1st simulation run to fit the model to 
the observed concentration in plasma40 (fitting Kpre and ka parameters). Open black dots refer to results from 
the 2nd simulation run to fit the model to the data set on cardiac concentrations41 (fitting Qpf and P parameters).
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parameter, corresponding in fact to the clearance of interstitial fluid, was estimated to be 0.78 [L/h] leading to 
predict the concentration of amitriptyline in pericardial fluid higher than expected.
The model incorporates drug metabolism in cardiac tissue as some CYP450 enzymes are highly expressed 
in the heart20,60, and according to Michaud et al., “could be extremely relevant for the local clearance of drugs 
and metabolite formation in the heart.” Indeed, amitriptyline is metabolized to nortriptyline, which together 
with its metabolites (Z-10-hydroxy-nortriptyline, E-10-hydroxy-nortriptyline) can contribute to cardiotoxicity61. 
Therefore, its concentration in the heart should also be taken into account in assessing the cardiac effect of the 
parent drug. That will be done by expanding the current model with the sub-model for the metabolite.
In order to assess the drug triggered cardiac effect, in vitro – in vivo extrapolation approach will be utilized. 
The patient-specific parameters and the individual drug concentration simulated by the PBPK heart model will 
be combined with the in vitro measured ion channels inhibition. Translation to the human in vivo situation will 
be done with the use of the Cardiac Safety Simulator (CSS) and expressed as the pseudoECG signal62,63. The 
pharmacodynamic models built-in to CSS that can be used are O’Hara-Rudy64 and ten Tusscher65,66 models. 
The simulation results, namely parameters characterizing depolarization (QRS) and repolarization (QT), will be 
compared against the available clinical data taking into account intra- and inter-individual human variability67,68.
Conclusion
We described the development of a four-compartmental heart model and its nesting into a whole-body PBPK 
model. The model integrated literature-derived data on cardiac anatomy and physiology and was used to predict 
amitriptyline concentration in venous plasma, epicardium, midmyocardium, endocardium, and pericardial fluid. 
Our PBPK heart sub-model requires further development, but it represents a first attempt to provide an active 
drug concentration in various locations within heart tissue with the use of a PBPK approach.
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